ICCM Stoklara Genel Bakış Ticari aşamada bir tıbbi cihaz şirketi olan IceCure Medical Ltd, kriyoablasyon sistemleri, tek kullanımlık malzemeler ve tümörlerin tedavisine yönelik teknolojilerin araştırılması, geliştirilmesi ve pazarlanmasıyla ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
IceCure Medical Ltd Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti IceCure Medical Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$1.12 52 Haftanın En Yüksek Seviyesi US$1.57 52 Haftanın En Düşük Seviyesi US$0.48 Beta 2.61 1 Aylık Değişim 57.26% 3 Aylık Değişim 82.71% 1 Yıllık Değişim 21.08% 3 Yıllık Değişim -65.96% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim 942.83%
Son Haberler & Güncellemeler
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16
IceCure Medical Ltd. Announces Interim Results from the ICESECRET Study of Cryoablation for Patients with Small Renal Masses Dec 05
Consensus revenue estimates fall by 13% Dec 03
No longer forecast to breakeven Nov 27
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 26
IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024 Nov 20 Daha fazla güncelleme görün
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16
IceCure Medical Ltd. Announces Interim Results from the ICESECRET Study of Cryoablation for Patients with Small Renal Masses Dec 05
Consensus revenue estimates fall by 13% Dec 03
No longer forecast to breakeven Nov 27
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 26
IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024 Nov 20 IceCure Medical Ltd has filed a Follow-on Equity Offering. Oct 16
IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues Sep 16
IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 Sep 12
U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology Aug 29
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 21
Forecast to breakeven in 2026 Aug 21
IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients Aug 15
IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024 Aug 13
IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth? Jul 31
New minor risk - Share price stability Jul 23
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Jul 23
IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense Jul 10
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes Jul 02
New minor risk - Shareholder dilution Jun 13
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025 Jun 06
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 30
IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024 May 23
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound–Guided Cryoablation for Early–Stage Primary Breast Cancer: A Follow–Up Study in Japan," in the Journal Breast Cancer on April 27, 2024 May 08 IceCure Medical Ltd, Annual General Meeting, May 20, 2024
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 03
Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes Apr 02
IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024 Mar 28
Price target increased by 14% to US$3.33 Mar 20
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study Mar 20
IceCure Medical Ltd. Announces Results from an Independent Study Mar 06
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study Feb 27
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company’s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda’S Prior Denial of Icecure’S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer Jan 30
IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million. Jan 14 IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Forecast to breakeven in 2026 Dec 31
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients Dec 13
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense Nov 29
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate Nov 29
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer Nov 17
IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023 Nov 09
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System Nov 08
New major risk - Revenue and earnings growth Sep 21
IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer Sep 21
Price target decreased by 15% to US$3.41 Sep 20
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 07
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 06
Second quarter 2023 earnings: EPS misses analyst expectations Aug 16
IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans? Aug 08
Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System Jul 25
New major risk - Financial position Jul 05
New major risk - Revenue and earnings growth Jun 29
IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023 May 16
Insufficient new directors May 01
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 31
Price target decreased by 14% to US$3.96 Mar 22
IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump Jan 24
IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems Jan 19
IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses Dec 21
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors Dec 07
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Dec 05
IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022 Nov 29
Price target decreased to US$4.58 Nov 16
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures Nov 09
Price target decreased to US$4.58 Oct 25
IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery Oct 20
IceCure gains 19% on seeking FDA nod for cancer treatment Oct 19
IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense® Aug 30
Second quarter 2022 earnings released Aug 17
IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022 Aug 10
IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors Jul 26
IceCure files application for approval of ProSense in Canada for tumors Jul 25
IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022 May 12
Price target decreased to US$7.58 Apr 27
Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020) Apr 02
Now 25% undervalued after recent price drop Feb 09
IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022 Jan 28
IceCure Medical: Advancing Cryotherapy For Cancer Treatment Jan 25
Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump Dec 22
IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America Dec 03
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 26
First half 2021 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1H 2020) Sep 29
Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer Sep 14
Icecure Medical Ordinary Shares Deleted from Other OTC Aug 27
IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting May 05
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East Feb 18
IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand Jan 06
IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million Oct 06
IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million. Aug 12 Hissedar Getirileri ICCM US Medical Equipment US Pazar 7D 7.7% -1.2% -2.7% 1Y 21.1% 10.0% 23.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: ICCM geçen yıl % 10 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: ICCM geçen yıl % 23.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is ICCM's price volatile compared to industry and market? ICCM volatility ICCM Average Weekly Movement 13.2% Medical Equipment Industry Average Movement 7.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
İstikrarlı Hisse Senedi Fiyatı: ICCM hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: ICCM 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında Ticari aşamada bir tıbbi cihaz şirketi olan IceCure Medical Ltd, tümörlerin tedavisi için kriyoablasyon sistemleri, tek kullanımlık malzemeler ve teknolojilerin araştırılması, geliştirilmesi ve pazarlanmasıyla ilgilenmektedir. Şirket, tümörlerin tedavisi için tek problu bir sistem olan ProSense sistemini ve ilgili tek kullanımlık malzemeleri; üroloji, onkoloji, dermatoloji, jinekoloji, genel cerrahi, göğüs cerrahisi ve proktolojiye ablasyon endikasyonları için IceSense3 sistemini sunmaktadır. Ayrıca, tek problu bir sistem olan XSense sistemini ve çoklu ve daha büyük tümörlerin tedavisi için çok problu bir sistem olan MultiSense sistemini geliştirmektedir.
Daha fazla göster IceCure Medical Ltd Temel Bilgiler Özeti IceCure Medical'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? ICCM temel i̇stati̇sti̇kler Piyasa değeri US$61.35m Kazançlar(TTM ) -US$13.83m Gelir(TTM ) US$3.67m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) ICCM gelir tablosu (TTM ) Gelir US$3.67m Gelir Maliyeti US$2.07m Brüt Kâr US$1.60m Diğer Giderler US$15.44m Kazançlar -US$13.83m
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/23 14:48 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları IceCure Medical Ltd 3 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Brian Kemp Dolliver Brookline Capital Markets Yi Chen H.C. Wainwright & Co. Anthony Vendetti Maxim Group
Göster 0 daha fazla analist 
